Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...

Europe’s pandemic preparedness capital is creating a rare opening for biotech innovators. Since COVID-19, the next pandemic is no longer abstract, and preparedness is no longer optional. Europe is ...

Unlike traditional drugs that bind directly to a protein’s active site, allosteric modulators act at separate regulatory sites, allowing them to fine-tune biological activity and act more like a ...

Life science companies regularly forge mergers and acquisition (M&A) deals to eliminate competition or to expand a pipeline. Recently, there has been a spike in M&As, but analysts point towards ...

Human immunodeficiency virus (HIV) research has come a long way since the virus was discovered in the 1980s. Antiretroviral therapy (ART) marked a turning point in HIV treatment, changing the lives of ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

The J.P. Morgan Healthcare Summit (JPM) serves as the world’s largest healthcare conference where healthcare professionals, scientists, and innovators meet with investors to set the agenda for the ...

The biopharma industry has seen its fair share of clinical and financial failures. When biotechs face setbacks, their stock values plummet and they lack the funds to develop new medicines, restructure ...